ECREASED NO available in the arterial wall may result in development of delayed cerebral vasospasm after SAH. 1, 45 This hypothesis is supported by the loss of nNOS in the vessel wall; 45 by the high affinity of NO to oxyhemoglobin, 14, 19, 33, 56 a purported factor responsible for vasospasm after SAH; 26, 43 and by the reversal 1 and prevention 44 of vasospasm with intracarotid delivery of NO. It has also been established that intravascular administration of L-arginine, the substrate for the NO-producing enzyme NOS, results in vasodilation 6, 7, 34, 37 and increased CBF. 4, 11, 14, 16, 34, 48, 57 Furthermore, intracisternal administration of L-arginine attenuates vasospasm of the basilar artery in dogs. 13, 22 The mechanism by which L-arginine induces these effects is unclear but may involve an increase in NO production by the upregulated eNOS 7, 11, 28, 48, 55 or iNOS 9, 15, 50 that is present after SAH occurs in macrophages, 15,38 reactive astrocytes, 2,9,36 and smooth-muscle cells stimulated by hemoglobin. 50 We hypothesized that intravascular administration of L-arginine might increase production of NO in the arterial wall or its vicinity, and we sought to determine whether parenteral delivery of L-arginine would reverse and/or prevent vasospasm in a primate model of SAH. Object. The reduction in the level of nitric oxide (NO) is a purported mechanism of delayed vasospasm after subarachnoid hemorrhage (SAH). Evidence in support of a causative role for NO includes the disappearance of nitric oxide synthase (NOS) from the adventitia of vessels in spasm, the destruction of NO by hemoglobin released from the clot into the subarachnoid space, and reversal of vasospasm by intracarotid NO. The authors sought to establish whether administration of L-arginine, the substrate of the NO-producing enzyme NOS, would reverse and/or prevent vasospasm in a primate model of SAH.
Abbreviations used in this paper: ANOVA = analysis of variance; AP = anteroposterior; CBF = cerebral blood flow; cGMP = cyclic guanosine monophosphate; eNOS = endothelial nitric oxide synthase; ICA = internal carotid artery; iNOS = inducible nitric oxide synthase; MCA = middle cerebral artery; nNOS = neural nitric oxide synthase; NO = nitric oxide; NOS = nitric oxide synthase; rCBF = regional cerebral blood flow; SAH = subarachnoid hemorrhage.
Materials and Methods

Experimental Design
The effect of parenteral administration of L-arginine on the diameter of the right MCA and on rCBF after placement of an autologous clot around the right MCA was examined in two experimental settings. In the short-term infusion group, five cynomolgus monkeys with delayed cerebral vasospasm of the right MCA (confirmed arteriographically on Day 7 after SAH) were tested during a continuous 3-minute intracarotid infusion of saline, followed by cerebral arteriography. Thirty minutes later, L-arginine was infused into the ICA in the same animals for 3 minutes. This infusion was immediately followed by cerebral arteriography. After an additional 30 minutes, two new L-arginine infusions, separated by 30 minutes, were administered. After the third intracarotid infusion of L-arginine, the final arteriogram was obtained. All infusions were performed under controlled physiological conditions (PCO 2 38-42 mm Hg). Arterial blood pressure was monitored using a transducer located in the left femoral artery, and end expiratory PCO 2 was controlled by the ventilation rate. Cortical rCBF in the distribution of the right MCA was monitored using a thermomonitoring probe placed under the dura in the right MCA territory during the infusions. 5 In the long-term infusion group, 11 cynomolgus monkeys were randomly allocated to one of two groups after onset of SAH. The monkeys received continuous intravenous infusion of either normal saline (control group, five animals) or L-arginine (10 Ϫ3 M, six animals) for 14 days beginning 24 hours after SAH occurred. Cerebral arteriography was performed before the onset of SAH and on Days 7 and 14 post-SAH. The monkeys were later killed.
All animals were tested while in a state of general anesthesia induced by 0.5% isoflurane/pancuronium; their systemic arterial blood pressure and end expiratory PCO 2 were continuously monitored.
Model of Cerebral Vasospasm
After induction of general anesthesia, all monkeys underwent right frontotemporal craniectomy with dissection of the arachnoid of the sylvian fissure. The techniques are fully described elsewhere. 10, 45 The right MCA was exposed and 5 ml of preclotted arterial blood collected from the left femoral artery was placed around the artery. The dura was closed watertight and the wound was closed in layers. Each monkey was extubated after recovery of the gag reflex.
Arteriographic Studies
To assess vasospasm, cerebral arteriography was performed preoperatively and on Days 7 (short-and long-term infusion experiments) and 14 (long-term infusion experiment) after surgery. 45 The monkeys were anesthetized by an intramuscular injection of ketamine (10 mg/kg) and xylazine (Rompun, 1 mg/kg). A femoral artery cutdown was performed under aseptic conditions and a No. 3 French polyethylene catheter was advanced, with the aid of a fluoroscope, to the right ICA. Contrast medium (0.75 ml of 60% Conray) was injected by hand. Subtraction images of the AP projections were acquired. Arteriographically demonstrated vasospasm was quantified relative to each animal's baseline arteriogram. 46 For grading vasospasm, the proximal 14-mm segment of the right MCA observed on both preoperative and postoperative AP arteriograms was measured using a computerized image analysis system, as previously described. 46 Vasospasm was classified on the basis of a comparison between the pre-and postoperative image measurements of the area of the right MCA observed in the AP view (11-25% reduction = mild vasospasm, 26-50% = moderate vasospasm, and Ͼ 50% = severe vasospasm).
Cerebral Blood Flow Measurement
After induction of general anesthesia, the short-term infusion group underwent a small right-sided parietal craniectomy. After the dura was opened, a CBF probe was slipped between the dura and the brain and placed over a region perfused by the right MCA. 5 The position of the probe was confirmed by a lateral skull x-ray film and by changes in CBF induced by an intracarotid bolus injection of saline. Regional CBF was measured continuously (one measurement every 4.5 seconds) before, during, and after intracarotid infusion of saline or L-arginine. To compare rCBF among groups of monkeys, CBF ratios were used; these were obtained for each monkey by normalizing the CBF measured during the saline and L-arginine infusions to the mean CBF of that monkey at a PCO 2 of 40 mm Hg immediately before starting the infusion. 53 Heart rate, blood pressure, rCBF, and PCO 2 were allowed to return to steady state (baseline) for at least 20 minutes between infusions.
Preparation and Delivery of L-Arginine
In the short-term infusion group, L-arginine was delivered directly, by an infusion pump, at the rate of 1.1 ml/minute through an intracarotid catheter placed in the ICA. The L-arginine solution was prepared to achieve an intracarotid concentration of 10 Ϫ6 M (calculated by assuming an average CBF in a monkey of 50 ml/100 g/ minute, brain weight of 80 g, and perfusion of two-thirds of the cerebral hemisphere by the ICA; the L-arginine concentration in the solution was 10 Ϫ5 M). 53 In the long-term infusion group, L-arginine (10 Ϫ3 M) was delivered using a D-infusor pump (20 ml/24 hours) through an indwelling catheter in the femoral vein. The pump, placed in a jacket on the back of the monkey, was changed every 24 hours. Saline was infused using the same method in the control group.
Levels of L-Arginine
The L-arginine levels in plasma samples, which were collected for the long-term infusion experiment at surgery and during postoperative arteriography, were measured using high-performance liquid chromatography. One hundred microliters of plasma was mixed with 100 l of 0.1 M hydrochloric acid containing 2 g of L-methionine sulfone. The mixture was filtered and centrifuged in a fixed-angle centrifuge for 20 minutes at 4000 G. The filtrate (40 l) was placed in a prewashed 13 ϫ 100-mm borosilicate glass culture tube; prewashed with 6 M hydrochloric acid, water, and 100% ethanol to remove impurities; and dried in a nitrogen atmosphere at 35˚C for 60 minutes. Samples were neutralized and derivatized. The dried residue was kept at Ϫ70˚C until reconstituted in 95 l of PICO-TAG diluent. Ten-microliter aliquots were analyzed. Highperformance liquid chromatography conditions and quantification were similar to those described by the manufacturer of the PICO-TAG system for analysis of free amino acids.
Statistical Analysis
For statistical analysis of data, we used ANOVA, the paired t-test, and Wilcoxon's signed-rank test. Significance was accepted at a probability value less than 0.05.
The animal protocol was reviewed by the National Institute of Neurological Disorders and Stroke Animal Care and Use Committee and met the National Institutes of Health guidelines for animal care.
Sources of Supplies and Equipment
Cerebral blood flow was monitored using a Saber thermomonitoring probe available from Flowtronix (Phoenix, AZ). 
Results
Short-Term Infusion Experiment
Seven days after SAH occurred, vasospasm of the right MCA developed in all five monkeys. Because we found no difference in the degree of vasospasm observed on the first and last arteriograms obtained after L-arginine infusions, only the results of the last arteriogram are presented. On arteriography performed immediately after intracarotid infusion of saline, the mean reduction in the right MCA area on the AP view was 44 Ϯ 7% compared with the preoperative area (PCO 2 38-42 mm Hg). The vessel AP area did not change in response to intracarotid L-arginine infusion (mean reduction in the right MCA area 45 Ϯ 9%; PCO 2 38-42 mm Hg; paired t-test, p = 0.2 between saline and L-arginine infusion groups). Intracarotid L-arginine infusion, however, increased cortical rCBF by 21 Ϯ 9.6% compared with saline infusion (p Ͻ 0.015; Fig. 1 ). Concurrent with this increase in rCBF, cerebrovascular resistance (mean arterial blood pressure/CBF 44 ) decreased in the infused ICA from the preinfusion value of 1.64 Ϯ 0.1 mm Hg/ml/100 g per minute to 1.43 Ϯ 0.4 mm Hg/ ml/100 g per minute (p Ͻ 0.001). There was no change in systemic mean arterial blood pressure during intracarotid L-arginine infusion compared with saline infusion (L-arginine group, 86 Ϯ 13 mm Hg; saline group, 83 Ϯ 13 mm Hg).
Long-Term Infusion Experiment
Moderate-to-severe vasospasm of the right MCA developed in all monkeys in the intravenous saline and L-arginine infusion groups on Day 7. The mean reduction in the right MCA AP area was 45 Ϯ 4% in the control group and 36 Ϯ 14% in the L-arginine group. The difference in the reduction in areas of the proximal segment of the right MCA between the control group (five animals) and the L-arginine group (six animals) was not significant (p = 0.16; Fig. 2 ). Vasospasm resolved, as is the normal course in this model, on Day 14 (the mean reduction in the right MCA area on the AP view was 3 Ϯ 13% in the saline group and 2 Ϯ 12% in the L-arginine group). There was no difference in the right MCA area between the pre-SAH observation and that made on post-SAH Day 14 (p = 0.2; Fig. 2) . Also, the difference in the degree of vasospasm on post-SAH Day 14 between the control and L-arginine groups was not significant (p = 0.4). The plasma L-arginine level (12.7 Ϯ 4 g/ml on Day 0, before intracarotid infusion of L-arginine) increased to 21.9 Ϯ 13.1 g/ml on Day 7 of the infusion (p Ͻ 0.05) and was 18.5 Ϯ 3.1 g/ ml on Day 14 (p Ͻ 0.03; Fig. 3 ). Plasma L-citrulline, a byproduct of NO production from L-arginine 31 was unchanged on Days 7 and 14 ( Fig. 3) .
Discussion
Continuous release of NO from endothelial cells is necessary to maintain resting cerebrovascular tone and basal CBF. 20, 29, 39, 53, 58 After SAH occurs, hemoglobin released from the clot binds NO, 8, 12, 16, 24, 56 troxidergic 54 neuronal endings in the adventitia, 45 interrupting vasodilation caused by NO. This decrease in NO availability in the arterial wall is a putative cause of vasospasm. 8, 45, 51, 56 Supporting this hypothesis are the reduced levels of cGMP, the second messenger for biological activity of NO, 19 in the wall of cerebral arteries exposed to blood 8, 23, 25 and the reversal 1 and prevention of vasospasm after an intracarotid infusion of NO. 44 In the primate model of SAH, vasospasm resolves approximately 14 days after onset of SAH. Production of NO from yet unidentified sources may explain this natural resolution of vasospasm.
Administration of L-arginine, a substrate for NO production, 32 increases NO production by endothelial cells in vitro, 7, 28 dilates vessels, 6, 7, 22, 34, 35, 37 and increases CBF in vivo. 4, 11, 14, 16, 34, 48, 57 Subsequently, L-arginine has been proposed as a potential therapy for delayed cerebral vasospasm. 13, 22, 51, 53 We sought to establish whether intracarotid or intravenous infusion of L-arginine reverses or prevents vasospasm in a primate model of SAH.
Short-Term Intracarotid Infusion of L-Arginine
Despite promising results in other models of SAH, 13, 22, 51 short-term ICA administration of L-arginine did not reverse vasospasm in our study. This discrepancy with prior studies may be due to a difference in L-arginine administration. In prior studies L-arginine was introduced intracisternally directly at the side of the vasospasm. 13, 22, 51 Because endothelial cells produce NO on exposure to L-arginine and because the endothelial cells of the vessels were in contact with the plasma containing the increased levels of L-arginine in our experiment, another cell type must be responsible for using L-arginine for the NO production that reversed vasospasm in previous studies.
Increased rCBF to the area supplied by the artery in spasm following short-term intracarotid administration of L-arginine, which induces NO release from endothelial cells, 7, 28, 37 supports earlier in vitro and in vivo observations that L-arginine dilates cerebral vessels and increases CBF. 6, 13, 22, 34, 35, 37, 48, 49 The mechanism of this increase in rCBF is not clear; 48 however, our findings and earlier observations 53 suggest that it is the small-resistance arterioles, rather than the conductive vessels of the brain that dilate in response to the high plasma levels of L-arginine. These findings also provide further evidence that NO, probably synthesized by eNOS, is an important mediator of rCBF regulation in primates. 29, 53 
Long-Term Intravenous Infusion of L-Arginine
In the long-term infusion experiment, a continuous increase in L-arginine plasma levels did not alter the degree, incidence, or time course of delayed cerebral vasospasm after SAH. We propose several explanations for the lack of effect of L-arginine on vasospasm. First, the level of L-arginine in plasma may not be a limiting factor in NO production by eNOS. Levels of L-arginine normally present in plasma may already saturate either the cellular uptake system for L-arginine or binding of L-arginine by eNOS, 34, 47, 48 precluding additional eNOS-dependent vasodilation of arteries in spasm. Second, the plasma L-arginine concentration may be too low to gain access to cells critical for NO production and vasospasm resolution, even though plasma levels were high. This possibility is supported by the attenuation of vasospasm after intracisternal administration of L-arginine. 13, 22, 51 Third, the excess L-arginine may have been preferentially used by another metabolic pathway. 32, 52, 63 This possibility is supported by the lack of influence a long-lasting increase in plasma L-arginine levels has on the levels of L-citrulline, a byproduct of the reaction releasing NO from L-arginine; 30 this is a test that is widely used for in vivo assessment of NO production. 21, 61, 62 Fourth, vasospasm produces structural and functional changes in endothelial cells, 3, 46 changes that may lead to dysfunction of eNOS. 8, 13, 51, 56 Consequently, eNOS may not respond to L-arginine with an increase in NO production. However, this mechanism seems unlikely to explain the negative results of our study, because excess L-arginine is known to correct eNOS dysfunction. 6, 7 
Possible Sources of NO Responsible for Spontaneous Resolution of Vasospasm
There are three known isoforms of NOS in the brain: nNOS (also known as NOS-1), iNOS (also known as NOS-2), and eNOS (also known as NOS-3). 14 2 and neurons (nNOS). 40, 46, 58 Nitric oxide that is produced by NOS from L-arginine by any of these cells binds to the heme moiety of soluble guanylate cyclase and promotes synthesis of cGMP. 14, 18, 31, 42 Increased cGMP levels in smooth-muscle cells lead to sequestration of Ca ++ from a myosin-actin complex, relaxation of the muscle cell, and vasodilation. 14, 31, 42 Thus, NO that is produced by any of the cells containing NOS and that diffuses to smooth-muscle cells in the cerebral arterial wall will produce a vasodilatory effect.
If we assume that production of NO is associated with resolution of vasospasm, the cells responsible for producing NO have not been identified. Endothelial cells are a candidate because eNOS activity remains present in the endothelium during vasospasm after SAH; 45 intravascular administration of L-arginine should increase endothelial production of NO 7, 28 and, consequently, relieve the spasm. Furthermore, because L-arginine does not readily cross the blood-brain barrier, 41 this effect is limited to endothelial cells. However, systemic administration of L-arginine did not reverse or prevent vasospasm. Thus, endothelial cells are an unlikely candidate. Neurons are an even more unlikely source of NO. Neuronal NOS is not present in the adventitia of the artery in spasm and its activity does not return even when vasospasm resolves. 45 Furthermore, the short halflife 16 of NO, coupled with the lack of nNOS-positive neurons in proximity to the spastic vessel, 56 suggests that nitroxidergic neurons of the brain are also unlikely to be responsible for resolution of vasospasm by NO production. The same limitations exclude iNOS and eNOS in reactive astrocytes 2,9,36 as a source of NO. Thus, iNOS present in macrophages that migrate to the arterial wall after SAH 3, 27, 46, 59 or iNOS expressed by smooth-muscle cells in response to hemin 50 released from the subarachnoid clot may provide NO to resolve vasospasm.
Conclusions
Intracarotid (short-lasting) and intravenous (long-lasting) infusion of L-arginine did not influence the incidence or degree of vasospasm. On the other hand, intracarotid infusion of L-arginine markedly increased rCBF in a primate model of SAH. These findings discourage the use of L-arginine as a treatment for vasospasm after onset of SAH.
